Abstract
Treatment of Alzheimer’s disease (AD) has recently focused on strategies which target deficits in the cholinergic system of the brain. Such focus is reasonable, given the loss of cholinergic neurons and associated choline acetyltransferase seen in the AD brain (Cutler et al., 1994). However, treatment with cholinergic compounds has proven complicated. All compounds thus far tested, including tacrine, appear to have limited efficacy, and treatment is often accompanied by significant adverse events. Many can affect plasma cholinesterases and have short half-lives as a result of rapid metabolism. More research is needed to find selective compounds with safer adverse event profiles.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cutler NR, Murphy MJ, Nash RJ, Prior PL (1990): Clinical safety, tolerance, and plasma levels of HP 029 in Alzheimer’s disease. J Clin Pharmacol 30:556–561.
Cutler NR, Sramek J J (1995a): Scientific and ethical concerns in clinical trials in Alzheimer’s patients: the bridging study. Eur J Clin Pharmacol 48:421–428.
Cutler NR, Sramek JJ (1995b): The target population in phase I clinical trials of cholinergic compounds in Alzheimer’s disease: the role of the “bridging study.” Alzheimer Dis Assoc Disord 9:139–145.
Cutler NR, Sramek J J, Veroff AE (1994): Alzheimer’s Disease: Optimizing Drug Development Strategies. Sussex England: John Wiley & Sons, Ltd.
Geller NL (1984): Design of phase I and II clinical trials in cancer: a statistician’s view. Cancer Invest 2:483–491.
Goldberg MR, Barchowsky A, McCrea J, et al (1991): Heptylphysostigmine (L-693,487): safety and Cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Abstr 2nd Int Symposium Advances in Alzheimer Therapy.
Puri SK, Ho I, Hsu R, Lassman HB (1990): Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer’s disease. J Clin Pharmacol 30:948–955.
Puri SK, Hsu R, Ho I, Lassman HB (1988): Single-dose safety, tolerance, and pharmacokinetics of HP029 in elderly men: a potential Alzheimer agent. Curr Ther Res 44:766–780.
Puri SK, Hsu RS, Ho I, Lassman HB (1989): Single dose safety, tolerance and pharmacokinetics of HP029 in healthy young men: A potential Alzheimeragent. J Clin Pharmacol 29:278–284.
Reece PA, Bockbrader H, Sedman AJ (1992): Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979. Clin Exp Pharmacol Physiol 21 (Suppl):58.
Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR (1994): A multiple-dose safety trial of eptastigmine in Alzheimer’s disease, with pharmacodynamic observations of red blood cell Cholinesterase. Life Sci 56:319–326.
Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR (1995a) The safety and tolerance of xanomeline tartrate in patients with Alzheimer’s disease. J Clin Pharmacol 35:800–806.
Sramek JJ, Sedman, AJ, Reece PA, Underwood B, Seifert RD, Bockbrader H, Cutler NR (1995b): Safety and tolerability of CI-979 in patients with Alzheimer’s disease. Life Sci 57:503–510.
Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR (1995c): A “bridging” (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer’s disease. Life Sci 57:1241–1248.
Tollefson GD, Bodick NC, Shannon HC (1994): Xanomeline: a potent and specific M1 agonist in the treatment of Alzheimer’s disease. Abstr American College Neuropsychopharmacology, December12–16.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Cutler, N.R., Sramek, J.J. (1997). The Bridging Study: Optimizing the Dose for Phase II/III. In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_58
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_58
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive